Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial

Abstract Regulatory T (T reg ) cells are powerful endogenous modulators of the immune response and their levels are reduced in patients with acute coronary syndromes (ACSs). Low-dose interleukin-2 (IL-2) has been shown to increase T reg cell levels, potentially providing an immunomodulatory strategy in ACSs. The IVORY trial was a double-blind, placebo-controlled, phase 2 trial in which patients presenting with ACSs and high-sensitivity C-reactive protein levels >2 mg l −1 were randomized in a 1:1 ratio to receive subcutaneous low-dose IL-2 (1.5 × 10 6 IU) or placebo for 8 weeks. [ 18 F]Fluorodeoxyglucose positron emission tomography–computed tomography of the ascending aorta and carotid arteries was…

• W
  Wellcome

  Award: 211100/Z/18/Z
• WT
  Wellcome Trust

  Award: 211100/Z/18/Z
• NI
  National Institute for Health and Care Research

  Awards: 203312, NIHR203312
• BH
  British Heart Foundation

  Awards: IA/F/23/275046, RE/24/130011, PG/22/10898
• DO
  Department of Health and Social Care
• MR
  Medical Research Council

  Awards: NIHR203312, MR/N028015/1
• EA
  Engineering and Physical Sciences Research Council
• NC
  NIHR Cambridge Biomedical Research Centre

  Award: NIHR203312